With its proprietary π-Icosa™ High-capacity and High-precision AAV serotype screening platform PackGene aims to identify tissue-specific and maximally infective AAV serotypes for clinical trial development. High infectivity and tissue specificity can ultimately reduce the dosage and production cost of AAV-based gene therapies while simultaneously increasing safety and efficacy.
Capacity
Our platform design results in higher library capacity
Precision
Higher precision AAV-serotype screening
Efficacy
High infectivity and tissue specificity can result in reduced dosage requirements that increase both safety and efficacy.
PackGene has three patents pending.
- Library＞1 billion mutants
- Screens AAVs for tissue specificity.